In terms of immune cytokines, NSCLC patients (n = 18) and control lung tissue samples (n = 5) were used to determine the relationship between malignant progression and IL-11 expression, which indicated that IL-11 was an oncogene in NSCLC. The gene discussed is IL11; the disease is non-small cell lung carcinoma.